<div id="readability-page-1"><p>In a report released today, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on Eupraxia Pharmaceuticals, with a price target of <span id="expert-recommendation-target">$11.00</span>.</p><h3>Meet Your ETF AI Analyst</h3><ul><li> Discover how TipRanks' <i>ETF</i> AI Analyst  can help you make smarter investment decisions </li><li>   Explore ETFs TipRanks' users love  and see what insights the <b><i>ETF</i> AI Analyst</b> reveals about the ones you follow.</li></ul> <p>According to TipRanks, Kluska is a 5-star analyst with an average return of <span>34.3%</span> and a 47.74% success rate. Kluska covers the Healthcare sector, focusing on stocks such as Monopar Therapeutics Inc, Celldex, and Taysha Gene Therapies.</p> <p>Currently, the analyst consensus on Eupraxia Pharmaceuticals is a Strong Buy with an average price target of C$14.52.</p></div>

EPRX

<p>Cantor Fitzgerald's Kristen Kluska reaffirms a Buy rating on Eupraxia Pharmaceuticals with a price target of $11.00. Kluska, a 5-star analyst with a 34.3% average return, focuses on the Healthcare sector. The analyst consensus for Eupraxia is a Strong Buy with an average price target of C$14.52.</p>

Cantor Fitzgerald Reaffirms Their Buy Rating on Eupraxia Pharmaceuticals (EPRX)